Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2002 1
2003 3
2004 7
2005 9
2006 5
2007 6
2008 4
2009 5
2010 3
2011 3
2012 7
2013 3
2015 1
2016 2
2017 1
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23618502

56 results

Results by year

Filters applied: . Clear all
Page 1
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer.
Denham JW, Steigler A, Tai KH, Joseph D, Matthews J, Atkinson C, Spry NA, Turner S, North J, Christie D, Wynne C, Lamb DS. Denham JW, et al. Radiother Oncol. 2013 May;107(2):123-8. doi: 10.1016/j.radonc.2013.03.025. Epub 2013 Apr 22. Radiother Oncol. 2013. PMID: 23618502 Free article. Clinical Trial.
Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.
Joseph D, Denham JW, Steigler A, Lamb DS, Spry NA, Stanley J, Shannon T, Duchesne G, Atkinson C, Matthews JHL, Turner S, Kenny L, Christie D, Tai KH, Gogna NK, Kearvell R, Murray J, Ebert MA, Haworth A, Delahunt B, Oldmeadow C, Attia J. Joseph D, et al. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):693-702. doi: 10.1016/j.ijrobp.2019.11.415. Int J Radiat Oncol Biol Phys. 2020. PMID: 32092343 Clinical Trial.
Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413. Roach M 3rd, et al. J Clin Oncol. 2003 May 15;21(10):1904-11. doi: 10.1200/JCO.2003.05.004. J Clin Oncol. 2003. PMID: 12743142 Clinical Trial.
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB. Teh BS, et al. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9. doi: 10.1016/j.ijrobp.2003.09.083. Int J Radiat Oncol Biol Phys. 2004. PMID: 15050332 Clinical Trial.
High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J. Vargas C, et al. Prostate Cancer Prostatic Dis. 2006;9(3):245-53. doi: 10.1038/sj.pcan.4500882. Epub 2006 Jun 20. Prostate Cancer Prostatic Dis. 2006. PMID: 16786040
56 results